2025; 1:100016.
. ERYTHROCYTE ALLOIMMUNIZATION IN CHILDREN WITH SICKLE CELL ANEMIA IN KILIFI, KENYA.The feasibility of pharmacokinetic-based dosing of hydroxyurea for children with sickle cell anaemia in Uganda: Baseline results of the alternative dosing and prevention of transfusions trial. British Journal of Clinical Pharmacology. 2025; 91:1865-1872.
.Malaria prophylaxis in sickle cell anaemia: some answers, more questions. The Lancet Infectious Diseases. 2025; 25:601-602.
.2025; 1:100001.
. Hydroxyurea to decrease stroke risk in children with sickle cell anemia: a systematic review and meta-analysis.The feasibility of pharmacokinetic-based dosing of hydroxyurea for children with sickle cell anaemia in Uganda: Baseline results of the alternative dosing and prevention of transfusions trial. British Journal of Clinical Pharmacology. 2025; 91:1865-1872.
.Primary Stroke Screening and Hydroxyurea Treatment for Sickle Cell Anemia in Pediatric Healthcare Settings in East and Central Africa: A Narrative Review of Capacity Gaps and Opportunities. Public Health Reviews. 2025; 46:1608359.
.2025; 211:a1272.
. Benefits of Hydroxyurea in Mitigating Early Onset Lung Disease in Children With Sickle Cell Anemia. American Journal of Respiratory and Critical Care Medicine.The modern use of hydroxyurea for children with sickle cell anemia. Haematologica: the hematology journal. 2025; 110:1061-1073.
.Stroke prevention in Hispanic children with sickle cell anemia: the SACRED trial. Blood Advances. 2025; 9:1791-1800.
.Pharmacokinetic-Guided Hydroxyurea to Reduce Transfusions in Ugandan Children with Sickle Cell Anemia: Study Design of the Alternative Dosing And Prevention of Transfusions Trial. Acta Haematologica. 2025; 148:208-219.
.The Voxelotor Effect: Decreased Affinity for New Drugs for Sickle Cell Disease?. Pediatric Blood and Cancer. 2025; 72:e31475.
.Hydroxyurea for Children and Adults with Hemoglobin SC Disease. 2025; 4:EVIDoa2400402.
.Globalization in clinical drug development for sickle cell disease. American Journal of Hematology. 2025; 100:4-9.
.Baseline characteristics of Ghanaian children and adults enrolled in PIVOT, a randomised clinical trial of hydroxyurea in HbSC disease in sub-Saharan Africa. British Journal of Haematology. 2024; 205:2470-2480.
.2024; 144:541.
. Newborn Screening for Sickle Cell Disease in Sub-Saharan Africa: Initial Results of the ASH Consortium on Newborn Screening in Africa (CONSA) Program. Blood.2024; 144:542.
. Hydroxyurea Pharmacokinetics in Children with Sickle Cell Anemia: Comparison of Global Cohorts. Blood.2024; 144:520.
. Building Capacity in Sub-Saharan Africa to Address Sickle Cell Disease: The Consortium on Newborn Screening in Africa (CONSA). Blood.2024; 144:289.
. Pharmacokinetic (PK)-Guided Dosing of Hydroxyurea for Tanzanian Children with Sickle Cell Anemia. Blood.2024; 144:5602.
. RED Blood Cell Alloimmunization in Sickle Cell Anaemia Patients in Kilifi, Kenya. Blood.2024; 144:2495.
. Effects of Splenomegaly in Children with Sickle Cell Anemia Treated with Hydroxyurea: Secondary Analysis of the Sphere Trial. Blood.2024; 144:5315.
. Growth Curves for Children Living with Sickle Cell Anemia in Kilifi County, Kenya, Do Not Follow Who Curves for Normal Children. Blood.2024; 144:2242.
. Stroke Training, Research, and Education Toward Capacity with Hydroxyurea (STRETCH). Blood.2024; 144:4032.
. Low Rate of Red Blood Cell Alloimmunization Among Transfused Children with Sickle Cell Anemia in Malawi without Pre-Transfusion Screening or Antigen Matching. Blood.Rationale, Development, and Validation of HdxSim, a Clinical Decision Support Tool for Model-Informed Precision Dosing of Hydroxyurea for Children with Sickle Cell Anemia. Clinical Pharmacology and Therapeutics. 2024; 116:670-677.
.A pharmacokinetic-pharmacodynamic analysis of l-glutamine for the treatment of sickle cell disease: Implications for understanding the mechanism of action and evaluating response to therapy. British Journal of Haematology. 2024; 205:1147-1158.
.Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial. The Lancet Haematology. 2024; 11:e425-e435.
.Successes and pitfalls in orphan drug development for sickle cell disease. Blood Advances. 2024; 8:2455-2465.
.Hydroxyurea reduces infections in children with sickle cell anemia in Uganda. Blood. 2024; 143:1425-1428.
.Reducing transfusion utilization for children with sickle cell anemia in sub-Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial. American Journal of Hematology. 2024; 99:625-632.
.A Population Pharmacokinetic Analysis of L-Glutamine Exposure in Patients with Sickle Cell Disease: Evaluation of Dose and Food Effects. Clinical Pharmacokinetics. 2024; 63:357-365.
.Angiopoietin-2 is associated with sickle cell complications, including stroke risk, and decreases with hydroxyurea therapy. 2024; 1:100001.
.The bold promise of gene therapy for sickle cell disease. British Journal of Haematology. 2024; 204:381-382.
.Screening for haemoglobin disorders: One size may not fit all. British Journal of Haematology. 2024; 204:26-28.
.Cost-Effectiveness of Hydroxyurea for Sickle Cell Anemia in a Low-Income African Setting: A Model-Based Evaluation of Two Dosing Regimens. Pharmacoeconomics Italian Research Articles. 2023; 41:1603-1615.
.2023; 142:797.
. Hydroxyurea Improves Intelligence Quotient Scores in Children with Sickle Cell Anemia and Elevated Transcranial Doppler Velocity. Blood.2023; 142:2530.
. A Novel, Rapid, and Accurate Quantitative Hydroxyurea Assay. Blood.2023; 142:1145.
. Effects of L-Glutamine on Biomarkers of Response in Sickle Cell Disease: A Pharmacokinetics-Pharmacodynamics Analysis. Blood.Codetection of Plasmodium falciparum in Children Hospitalized With Dengue Fever in the Dominican Republic. The Pediatric Infectious Disease Journal. 2023; 42:965-968.
.Simultaneous adjunctive treatment of malaria and its coevolved genetic disorder sickle cell anemia. Blood Advances. 2023; 7:5970-5981.
.Efficacy, safety, and pharmacokinetics of a new, ready-to-use, liquid hydroxyurea in children with sickle cell anemia. Blood Advances. 2023; 7:4319-4322.
.Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission. The Lancet Haematology. 2023; 10:e633-e686.
.Sustained and Boosted Antibody Responses in Breast Milk After Maternal SARS-CoV-2 Vaccination. Breastfeeding Medicine. 2023; 18:612-620.
.Zinc for infection prevention in children with sickle cell anemia: a randomized double-blind placebo-controlled trial. Blood Advances. 2023; 7:3023-3031.
.Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination. Vaccine. 2023; 41:4183-4189.
.Hydroxyurea pharmacokinetics and precision dosing in low-resource settings. Frontiers in Molecular Biosciences. 2023; 10:1130206.
.Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: Current evidence and knowledge gaps. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023; 43:419-429.
.Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. The Lancet Haematology. 2023; 10:e261-e271.
.Genome-wide association study of early ischaemic stroke risk in Brazilian individuals with sickle cell disease implicates ADAMTS2 and CDK18 and uncovers novel loci. British Journal of Haematology. 2023; 201:343-352.
.Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa. Blood. 2023; 141:1402-1410.
.Stroke Prevention with Hydroxyurea Enabled through Research and Education: A Phase 2 Primary Stroke Prevention Trial in Sub-Saharan Africa. Acta Haematologica. 2023; 146:95-105.
.Lack of hydroxyurea-associated mutagenesis in pediatric sickle cell disease patients. Environmental and Molecular Mutagenesis. 2023; 64:167-175.
.The Consortium on Newborn Screening in Africa for sickle cell disease: study rationale and methodology. Blood Advances. 2022; 6:6187-6197.
.Blood diseases in Africa: Redressing unjust disparities is an urgent unmet need. American Journal of Hematology. 2022; 97:1505-1506.
.2022; 140:8168-8169.
. Hydroxyurea Pharmacokinetics in Young Children with Sickle Cell Anemia: Results from the Therapeutic Response Evaluation and Adherence Trial (TREAT). Blood.2022; 140:8256-8257.
. Evaluation of Dosage and Food Effect on L-Glutamine Exposure for Sickle Cell Anemia: A Population Pharmacokinetic Analysis. Blood.2022; 6:1.
. O‐01: HYDROXYUREA REDUCES THE TRANSFUSION BURDEN IN CHILDREN WITH SICKLE CELL ANEMIA IN SUB‐SAHARAN AFRICA: THE REACH EXPERIENCE. HemaSphere.2022; 6:13.
. PI‐08: HIGH DISEASE BURDEN, MORBIDITY AND MORTALITY AMONG CHILDREN WITH SICKLE CELL ANAEMIA IN UGANDA. HemaSphere.2022; 6:7-8.
. O‐12: BUILDING LOCAL CAPACITY FOR HYDROXYUREA PHARMACOKINETICS AND PRECISION DOSING IN LOW‐RESOURCE SETTINGS. HemaSphere.New therapeutics for children with sickle cell disease: A time for celebration, caution, or both?. Pediatric Blood and Cancer. 2022; 69:e29805.
.US News & World Report and quality metrics: Inclusion of sickle cell disease is a matter of equity. Pediatric Blood and Cancer. 2022; 69:e29679.
.Case Report: β-thalassemia major on the East African coast. Wellcome Open Research. 2022; 7:188.
.Assessment of Plasmodium falciparum Artemisinin Resistance Independent of kelch13 Polymorphisms and with Escalating Malaria in Bangladesh. Editor, Bhanot P. mBio. 2022; 13:e0344421.
.Reproductive equity: preserve the reserve. Blood. 2022; 139:963-965.
.Decreased parasite burden and altered host response in children with sickle cell anemia and severe anemia with malaria. Blood Advances. 2021; 5:4710-4720.
.Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial. British Journal of Haematology. 2021; 195:612-620.
.Increased oxygen affinity: to have and to hold. Blood. 2021; 138:1094-1095.
.Microscope diagnosis of MYH9-related thrombocytopenia. Blood. 2021; 138:1000.
.Rapid and automated quantitation of dense red blood cells: A robust biomarker of hydroxyurea treatment response. Blood Cells, Molecules, and Diseases. 2021; 90:102576.
.Knowledge gaps in reproductive and sexual health in girls and women with sickle cell disease. British Journal of Haematology. 2021; 194:970-979.
.Operational analysis of the national sickle cell screening programme in the Republic of Uganda. African Journal of Laboratory Medicine. 2021; 10:1303.
.Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia. British Journal of Haematology. 2021; 194:617-625.
.Seroprevalence of SARS-CoV-2 infection in Cincinnati Ohio USA from August to December 2020. Editor, Kumar B. PloS one. 2021; 16:e0254667.
.Newborn screening for sickle cell disease in sub-Saharan Africa: Is the glass half-full yet?. Pediatric Blood and Cancer. 2021; 68:e29137.
.Absence of hydroxyurea-induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia. British Journal of Haematology. 2021; 194:252-266.
.Prospective Newborn Screening for Sickle Cell Disease and Other Inherited Blood Disorders in Central Malawi. International Journal of Public Health. 2021; 66:629338.
.Transfusion management of severe anaemia in African children: a consensus algorithm. British Journal of Haematology. 2021; 193:1247-1259.
.Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience. Pediatric Blood and Cancer. 2021; 68:e29008.
.Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial. JMIR Research Protocols. 2021; 10:e27650.
.Hydroxyurea Pharmacokinetics in Pediatric Patients After Total Pancreatectomy With Islet Autotransplantation. The Journal of Clinical Pharmacology. 2021; 61:547-554.
.Automated Oxygen Gradient Ektacytometry: A Novel Biomarker in Sickle Cell Anemia. Frontiers in Physiology. 2021; 12:636609.
.2021; 147:230-231.
. Bedside Expedited Testing for Anemia in Tanzania: the BETA Study. Pediatrics.There's safety in numbers. Blood. 2021; 137:729-731.
.Electrochemical Determination of Hydroxyurea in a Complex Biological Matrix Using MoS2-Modified Electrodes and Chemometrics. Biomedicines. 2021; 9:6.
.Trends in sickle cell trait and disease screening in the Republic of Uganda, 2014-2019. Tropical Medicine and International Health. 2021; 26:23-32.
.